Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage.

Jaideep Singh Kristy L Jackson Haoyun FangAudrey GumantiBethany ClaridgeFeng Shii Tang Helen Kiriazis Ekaterina SalimovaAlex M ParkerCameron J Nowell Owen L Woodman David W Greening Rebecca Helen Ritchie Geoffrey A Head Chengxue Helena Qin

Published in: Cardiovascular research (2024)

We have demonstrated, for the first time, that the FPR agonist Cmpd17b powerfully limits hypertension-induced end-organ damage, consistent with proteome networks, supporting development of pro-resolution FPR-based therapeutics for treatment of systemic hypertension complications.

Keyphrases

blood pressure
high glucose
diabetic rats
oxidative stress
drug induced
endothelial cells
single molecule
combination therapy
stress induced